Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - rurioctocog alfa pegol -

Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - rurioctocog alfa pegol -

Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

takeda malaysia sdn bhd - rurioctocog alfa pegol -

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

takeda new zealand limited - rurioctocog alfa pegol 1000 [iu];  ;   - powder for injection with diluent - 1000 iu - active: rurioctocog alfa pegol 1000 [iu]     excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

takeda new zealand limited - rurioctocog alfa pegol 2000 [iu];  ;   - powder for injection with diluent - 2000 iu - active: rurioctocog alfa pegol 2000 [iu]     excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

takeda new zealand limited - rurioctocog alfa pegol 250 [iu];  ;   - powder for injection with diluent - 250 iu - active: rurioctocog alfa pegol 250 [iu]     excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

takeda new zealand limited - rurioctocog alfa pegol 500 [iu];  ;   - powder for injection with diluent - 500 iu - active: rurioctocog alfa pegol 500 [iu]     excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

takeda new zealand limited - rurioctocog alfa pegol 1500 [iu];  ;   - powder for injection with diluent - 1500 iu - active: rurioctocog alfa pegol 1500 [iu]     excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

takeda new zealand limited - rurioctocog alfa pegol 3000 [iu];  ;   - powder for injection with diluent - 3000 iu - active: rurioctocog alfa pegol 3000 [iu]     excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

takeda new zealand limited - rurioctocog alfa pegol 750 [iu];  ;   - powder for injection with diluent - 750 iu - active: rurioctocog alfa pegol 750 [iu]     excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.